<p>Atea Pharmaceuticals, Inc.（納斯達克代碼：AVIR - 獲取免費報告）的股票在週二交易中上漲了 5.9%。該股最高交易價為 5.40 美元，最後交易價為 5.38 美元。在午盤交易中，約有 325,173 股被交易，較平均每日交易量 671,832 股下降了 52%。該股此前收盤價為 5.08 美元。</p>
<p>獲取 <strong>Atea Pharmaceuticals</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<p>另外，Weiss Ratings 在 1 月 21 日的研究報告中重申了對 Atea Pharmaceuticals 股票的 “賣出（d-）” 評級。一位股票研究分析師給予該股 “強烈買入” 評級，一位給予 “持有” 評級，另一位則給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股的平均評級為 “持有”，共識目標價為 6.00 美元。</p>
<p><strong>查看我們關於 Atea Pharmaceuticals 的最新股票報告</strong></p>
<h2>Atea Pharmaceuticals 股票上漲 5.9%</h2>
<p>該股市值為 4.2862 億美元，市盈率為-2.77，貝塔值為 0.21。該公司的 50 日移動平均線為 4.85 美元，200 日移動平均線為 3.78 美元。</p>
<p>Atea Pharmaceuticals（納斯達克代碼：AVIR - 獲取免費報告）最近於 3 月 5 日發佈了季度財報。該公司報告本季度每股收益為（0.57 美元），低於市場共識預期的（0.49 美元）0.08 美元。股票研究分析師預計 Atea Pharmaceuticals, Inc.在當前年度將發佈-2.01 美元的每股收益。</p>
<h2>機構投資者對 Atea Pharmaceuticals 的看法</h2>
<p>一些對沖基金和其他機構投資者最近買入和賣出了該公司的股票。Prudential Financial Inc.在第二季度以 36,000 美元的估值購買了 Atea Pharmaceuticals 的新頭寸。RFG Advisory LLC 在第四季度以 53,000 美元的價值購買了 Atea Pharmaceuticals 的股份。BNP Paribas Financial Markets 在第三季度將其在 Atea Pharmaceuticals 的股份增加了 57.7%。BNP Paribas Financial Markets 現在擁有 19,913 股該公司的股票，價值 58,000 美元，此前在上個季度又購買了 7,286 股。SG Americas Securities LLC 在第三季度以 59,000 美元的估值收購了 Atea Pharmaceuticals 的新股份。最後，Jump Financial LLC 在第四季度將其在 Atea Pharmaceuticals 的持股增加了 36.5%。Jump Financial LLC 現在擁有 19,113 股該公司的股票，價值 68,000 美元，此前在上個季度又購買了 5,106 股。86.67% 的股票由機構投資者和對沖基金持有。</p>
<h2>Atea Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Atea Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於針對 RNA 病毒的口服抗病毒治療的發現和開發。該公司的主導項目 AT-527 是一種直接作用的核苷酸前藥，已從羅氏公司獲得許可，並正在評估作為 2019 冠狀病毒病（COVID-19）的潛在治療方案。除了 COVID-19 的努力外，Atea 的產品管線還包括針對丙型肝炎病毒和新興 RNA 病原體的其他小分子候選藥物，利用其專有的核苷酸化學平台來解決傳染病中顯著未滿足的醫療需求。</p>
<p>Atea 成立於 2014 年，總部位於馬薩諸塞州劍橋市，在大波士頓地區運營研究實驗室，並在北美、歐洲和部分亞洲進行臨牀研究。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Atea Pharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Atea Pharmaceuticals 嗎？</h2>
<p>在你考慮 Atea Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Atea Pharmaceuticals 並不在名單上。</p>
<p>雖然 Atea Pharmaceuticals 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

AVIR

<p>Atea Pharmaceuticals（納斯達克代碼：AVIR）股價在交易中上漲 5.9%，至 5.38 美元，儘管交易量較平均水平下降了 52%。分析師對該股票的評級不一，分別為一項強烈買入、一項持有和一項賣出。公司報告的季度每股虧損為（0.57 美元），未能達到預期。機構投資者持有該股票的 86.67%。Atea 專注於開發抗病毒治療，包括針對 COVID-19 和丙型肝炎的治療</p>

<p>Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) were up 5.9% during trading on Tuesday . The stock traded as high as $5.40 and last traded at $5.38. Approximately 325,173 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 671,832 shares. The stock had previously closed at $5.08.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals, Inc.（納斯達克代碼：AVIR - 獲取免費報告）的股票在週二交易中上漲了 5.9%。該股最高交易價為 5.40 美元，最後交易價為 5.38 美元。在午盤交易中，約有 325,173 股被交易，較平均每日交易量 671,832 股下降了 52%。該股此前收盤價為 5.08 美元。</p>
</div><p>Get <strong>Atea Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Atea Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Atea Pharmaceuticals in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and a consensus target price of $6.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 1 月 21 日的研究報告中重申了對 Atea Pharmaceuticals 股票的 “賣出（d-）” 評級。一位股票研究分析師給予該股 “強烈買入” 評級，一位給予 “持有” 評級，另一位則給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股的平均評級為 “持有”，共識目標價為 6.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Atea Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Atea Pharmaceuticals 的最新股票報告</strong></p>
</div><h2>Atea Pharmaceuticals Trading Up 5.9%</h2>
<div class="lb-trans"><h2>Atea Pharmaceuticals 股票上漲 5.9%</h2>
</div><p>The stock has a market capitalization of $428.62 million, a P/E ratio of -2.77 and a beta of 0.21. The firm's fifty day moving average is $4.85 and its 200-day moving average is $3.78.</p>
<div class="lb-trans"><p>該股市值為 4.2862 億美元，市盈率為-2.77，貝塔值為 0.21。該公司的 50 日移動平均線為 4.85 美元，200 日移動平均線為 3.78 美元。</p>
</div><p>Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08). Equities research analysts expect that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current year.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals（納斯達克代碼：AVIR - 獲取免費報告）最近於 3 月 5 日發佈了季度財報。該公司報告本季度每股收益為（0.57 美元），低於市場共識預期的（0.49 美元）0.08 美元。股票研究分析師預計 Atea Pharmaceuticals, Inc.在當前年度將發佈-2.01 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Atea Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Atea Pharmaceuticals 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Prudential Financial Inc. bought a new position in Atea Pharmaceuticals in the 2nd quarter valued at $36,000. RFG Advisory LLC bought a new stake in shares of Atea Pharmaceuticals during the fourth quarter worth $53,000. BNP Paribas Financial Markets increased its stake in shares of Atea Pharmaceuticals by 57.7% in the third quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company's stock valued at $58,000 after buying an additional 7,286 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Atea Pharmaceuticals in the third quarter valued at $59,000. Finally, Jump Financial LLC raised its holdings in shares of Atea Pharmaceuticals by 36.5% in the fourth quarter. Jump Financial LLC now owns 19,113 shares of the company's stock valued at $68,000 after buying an additional 5,106 shares during the last quarter. 86.67% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近買入和賣出了該公司的股票。Prudential Financial Inc.在第二季度以 36,000 美元的估值購買了 Atea Pharmaceuticals 的新頭寸。RFG Advisory LLC 在第四季度以 53,000 美元的價值購買了 Atea Pharmaceuticals 的股份。BNP Paribas Financial Markets 在第三季度將其在 Atea Pharmaceuticals 的股份增加了 57.7%。BNP Paribas Financial Markets 現在擁有 19,913 股該公司的股票，價值 58,000 美元，此前在上個季度又購買了 7,286 股。SG Americas Securities LLC 在第三季度以 59,000 美元的估值收購了 Atea Pharmaceuticals 的新股份。最後，Jump Financial LLC 在第四季度將其在 Atea Pharmaceuticals 的持股增加了 36.5%。Jump Financial LLC 現在擁有 19,113 股該公司的股票，價值 68,000 美元，此前在上個季度又購買了 5,106 股。86.67% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Atea Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Atea Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company's lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea's pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於針對 RNA 病毒的口服抗病毒治療的發現和開發。該公司的主導項目 AT-527 是一種直接作用的核苷酸前藥，已從羅氏公司獲得許可，並正在評估作為 2019 冠狀病毒病（COVID-19）的潛在治療方案。除了 COVID-19 的努力外，Atea 的產品管線還包括針對丙型肝炎病毒和新興 RNA 病原體的其他小分子候選藥物，利用其專有的核苷酸化學平台來解決傳染病中顯著未滿足的醫療需求。</p>
</div><p>Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.</p>
<div class="lb-trans"><p>Atea 成立於 2014 年，總部位於馬薩諸塞州劍橋市，在大波士頓地區運營研究實驗室，並在北美、歐洲和部分亞洲進行臨牀研究。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Atea Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Atea Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Atea Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Atea Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Atea Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Atea Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Atea Pharmaceuticals 並不在名單上。</p>
</div><p>While Atea Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Atea Pharmaceuticals 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Atea Pharmaceuticals（NASDAQ:AVIR）股價上漲 5.9% - 以下是原因